Evaluation of the effectiveness of dexmedetomidineine sedation of COVID-19 critically ill patients
Phase 3
Recruiting
- Conditions
- The effect of dexmedomedine in COVID-19 patients..COVID-19,virus identifiedU07.1
- Registration Number
- IRCT20110425006280N13
- Lead Sponsor
- Vice President of Research Guilan university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients aged 18 to 75 years admitted to the Intensive Care unit
clinical diagnosis of respiratory distress and breathing distress
Oxygen saturation less than 93% or positive polymerase chain reaction test
connected to non-invasive or invasive ventilation
requiring sedative administration.
Exclusion Criteria
Pregnant patients
Known allergies to opioid drugs or dexmedomeidine.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical Symptoms of COVID-19. Timepoint: The total time of the study will be done within 15 days at 8-hour intervals. Method of measurement: questionnaire form.
- Secondary Outcome Measures
Name Time Method Relaxation of critically ill patients with 19 ICUs in terms of agitation and delirium. Timepoint: The duration of examination of patients in the ICU is 15 days. This scoring is done for patients at intervals of 8 hours and the average will be evaluated. Method of measurement: During the period of hospitalization, they will be examined for vital signs and intubation. Delirium and agitation will be assessed based on the Richmond Restlessness-Drowsiness Scale (RSAA).This scale is defined in the scoring range between 0-1.According to this scale, agitation includes items: +1 restless, +2 agitated, 3+ very agitated, +4 fighter.In the case of delirium, it is divided into 0 alert and calm, -1 drowsiness, -2 mild sedation, -3 moderate sedation, -4 deep anesthesia, and -5 absence of any awakening.